Intellia Therapeutics, Inc. SEC filings NTLA
Intellia Therapeutics, Inc. has 721 filings in SEC EDGAR's recent list, going back to Sep 3, 2015. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 8, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Apr 29, 2026 | — |
| 424B5 | Prospectus supplement | Apr 27, 2026 | — |
| 424B5 | Prospectus supplement | Mar 2, 2026 | — |
| S-8 | Employee stock plan registration | Feb 26, 2026 | — |
| S-8 | Employee stock plan registration | Jun 11, 2025 | — |
| S-8 | Employee stock plan registration | Feb 28, 2025 | — |
| S-8 | Employee stock plan registration | Jul 18, 2024 | — |
| 424B5 | Prospectus supplement | Feb 26, 2024 | — |
| 424B5 | Prospectus supplement | Feb 23, 2024 | — |
| S-8 | Employee stock plan registration | Feb 22, 2024 | — |
| S-3ASR | Automatic shelf registration | Nov 24, 2023 | — |
| S-8 | Employee stock plan registration | Feb 23, 2023 | — |
| 424B5 | Prospectus supplement | Dec 1, 2022 | — |
| 424B5 | Prospectus supplement | Mar 4, 2022 | — |
| S-8 | Employee stock plan registration | Feb 24, 2022 | — |
| 424B5 | Prospectus supplement | Jul 1, 2021 | — |
| 424B5 | Prospectus supplement | Jun 28, 2021 | — |
| S-8 | Employee stock plan registration | Feb 26, 2021 | — |
| 424B5 | Prospectus supplement | Dec 2, 2020 | — |
| 424B5 | Prospectus supplement | Nov 30, 2020 | — |
| S-3ASR | Automatic shelf registration | Nov 30, 2020 | — |
| 424B5 | Prospectus supplement | Jun 3, 2020 | — |
| 424B5 | Prospectus supplement | Jun 1, 2020 | — |
| S-8 | Employee stock plan registration | Feb 27, 2020 | — |
| S-3/A | Filing | Aug 30, 2019 | — |
| S-3 | Shelf registration | Aug 23, 2019 | — |
| S-8 | Employee stock plan registration | Feb 27, 2019 | — |
| POS AM | Filing | Feb 27, 2019 | — |
| S-3ASR | Automatic shelf registration | Oct 12, 2018 | — |
| 424B5 | Prospectus supplement | Nov 3, 2017 | — |
| 424B5 | Prospectus supplement | Nov 1, 2017 | — |
| S-8 | Employee stock plan registration | Jun 5, 2017 | — |
| S-3 | Shelf registration | Jun 5, 2017 | — |
| S-8 | Employee stock plan registration | May 6, 2016 | — |
| 424B4 | Prospectus | May 6, 2016 | — |
| S-1MEF | Filing | May 5, 2016 | — |
| FWP | Free writing prospectus | May 5, 2016 | — |
| S-1/A | Amended registration statement | May 5, 2016 | — |
| S-1/A | Amended registration statement | Apr 27, 2016 | — |
| S-1/A | Amended registration statement | Apr 19, 2016 | — |
| S-1/A | Amended registration statement | Apr 12, 2016 | — |
| S-1 | Registration statement | Apr 11, 2016 | — |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NTLA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1652130
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.